Stroke Clinical Trials | Department of Medicine | School of Medicine

The stroke research unit at Queen’s has an active research program and is involved in multiple research projects. These include observational studies and randomized clinical trials. Currently, we are participating as a recruiting site for 7 multi-Centre national and international randomized clinical trials in hyperacute stroke and secondary stroke prevention. In addition, there are multiple ongoing observational studies/research projects exploring interesting and emerging areas of stroke research.

The details of the stroke clinical trials is provided below

AcT-RCCT

AcT-RCCT: Alteplase Compared to Tenecteplase in Patients with Acute Ischemic Stroke: QuICR & OPTIMISE Registry Based Pragmatic Randomized Controlled Trial

Purpose: To compare Alteplase with Tenecteplase for stroke treatment to determine if patients who receive Tenecteplase do as well as those who receive Alteplase when followed out to 3 months after their stroke.

Sponsor: University of Calgary

ClinicalTrials.gov Identifier: NCT03889249

Local Principal Investigator: Dr. Ramana Appireddy

ARCADIA

ARCADIA: AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke

Purpose: The primary aim is to test the hypothesis that apixaban is superior to aspirin for the prevention of recurrent stroke in subjects with cryptogenic ischemic stroke and atrial cardiopathy. The secondary aim is to test the hypothesis that the relative efficacy of apixaban over aspirin increases with the severity of atrial cardiopathy.

Sponsor: Columbia University

ClinicalTrials.gov Identifier: NCT03192215

Local Principal Investigator: Dr. Shirin Jalini

CATIS-ICAD

CATIS-ICAD: Combination Antithrombotic Treatment for prevention of recurrent Ischemic Stroke in IntraCranial Atherosclerotic Disease: Protocol for a pilot randomized trial

Purpose: To demonstrate feasibility of recruitment. To acquire safety data about combination antithrombotic therapy in this specific patient population

Sponsor: Population Health Research Institute

ClinicalTrials.gov Identifier: NCT04142125

Local Principal Investigator: Dr. Ramana Appireddy

CONVINCE

CONVINCE: COlchicine for preventioN of Vascular Inflammation in Non- CardioEmbolic Stroke) - a Randomised Clinical Trial of Low-dose Colchicine for Secondary Prevention After Stroke. A Multicentre, prospective randomized open label clinical trial

Purpose: The primary aim is to compare low-dose colchicine (0.5mg/day) plus usual care, to usual care alone, to prevent non-fatal recurrent ischaemic stroke and coronary events and vascular death after non-severe, noncardioembolic TIA/stroke.

Sponsor: University College Dublin, Ireland

ClinicalTrials.gov Identifier: NCT02898610

Local Principal Investigator: Dr. Albert Jin

ENRICH-AF

ENRICH-AF: EdoxabaN foR IntraCranial Hemorrhage survivors with Atrial Fibrillation

Purpose: To assess whether edoxaban (60/30 mg daily) compared to non-anticoagulant medical therapy (either no antithrombotic therapy or antiplatelet monotherapy) reduces the risk of stroke (composite of ischemic, hemorrhagic and unspecified stroke) in high-risk atrial fibrillation (CHA2DS2-VASc score ≥2) patients with previous intracranial hemorrhage.

Sponsor: Population Health Research Institute

ClinicalTrials.gov Identifier: NCT03950076

Local Principal Investigator: Dr. Shirin Jalini

ESCAPE-NEXT

ESCAPE-NEXT: A Multicentre, Randomized, Double-blinded, Placebo-controlled, Parallel Group, Single-dose Design to Determine the Efficacy and Safety of Nerinetide in Participants With Acute Ischemic Stroke Undergoing Endovascular Thrombectomy Excluding Thrombolysis

Purpose: To determine if a single dose of nerinetide can reduce neurological disability in people who have had a stroke and are selected for endovascular therapy without the use of a tissue plasminogen activator (alteplase, tenecteplase, or equivalent).

Sponsor: NoNo Inc.

ClinicalTrials.gov Identifier: NCT04462536

Local Principal Investigator: Dr. Albert Jin

TEMPO2

TEMPO2: Multicentre, prospective randomized open label, blinded-endpoint (PROBE) controlled trial of thrombolysis with low dose Tenecteplase (TNK-tPA) versus standard of care in the prevention of disability at 3 months in minor ischemic stroke with proven acute symptomatic occlusion

Purpose: To demonstrate the efficacy of using TNK-tPA to treat minor ischemic stroke with proven arterial occlusion.

Sponsor: University of Calgary

ClinicalTrials.gov Identifier: NCT02398656

Local Principal Investigator: Dr. Ramana Appireddy